Evidence map›Paper›PMID 36578284›Full record

ArticleClinical & translational immunology2022

Circulating CCR6

Florentina Aglas-Leitner, Pierre Juillard, Anette Juillard, Scott N Byrne, Simon Hawke, Georges E Grau, Felix Marsh-Wakefield

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & translational immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. The role of CD56Journal of neuroinflammation · 2024
    Review
  3. ILC3: a case of conflicted identity.Frontiers in immunology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Florentina Aglas-LeitnerVascular Immunology Unit, School of Medical Sciences, Faculty of Medicine and Health The University of Sydney Sydney NSW Australia.ORCID https://orcid.org/0000-0001-6064-6514
Pierre JuillardVascular Immunology Unit, School of Medical Sciences, Faculty of Medicine and Health The University of Sydney Sydney NSW Australia.
Anette JuillardVascular Immunology Unit, School of Medical Sciences, Faculty of Medicine and Health The University of Sydney Sydney NSW Australia.
Scott N ByrneCentre for Immunology and Allergy Research The Westmead Institute for Medical Research Sydney NSW Australia.ORCID https://orcid.org/0000-0003-3029-1710
Simon HawkeVascular Immunology Unit, School of Medical Sciences, Faculty of Medicine and Health The University of Sydney Sydney NSW Australia.
Georges E GrauVascular Immunology Unit, School of Medical Sciences, Faculty of Medicine and Health The University of Sydney Sydney NSW Australia.
Felix Marsh-WakefieldVascular Immunology Unit, School of Medical Sciences, Faculty of Medicine and Health The University of Sydney Sydney NSW Australia.ORCID https://orcid.org/0000-0002-6839-7628
The University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The role of innate lymphoid cells (ILC), particularly helper ILC, in the pathogenesis of multiple sclerosis (MS) is not well understood. Here, we present a comprehensive analysis of peripheral ILC subsets in MS patients prior and after alemtuzumab administration using mass cytometry. Methods: Circulating ILC were analysed by mass cytometry in MS patients before and after alemtuzumab. These were compared with non-MS controls. MS-related shifts among ILC immunophenotypes were further elucidated by fast interpolation-based t-SNE (Flt-SNE) dimensionality reduction. Results: Neither natural killer (NK) cells nor helper ILC (ILC1, ILC2 and ILC3) levels were altered following alemtuzumab treatment. However, CD56 Conclusion: CD56

Indexed as

alemtuzumabCCR6ILCMSNK cells

Identifiers

PMID36578284
PMCPMC9782758
OpenAlexW4312728190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.